Wuxi Jialing Pharmaceutical

Wuxi Jialing Pharmaceutical is a clinical-stage biopharmaceutical company based in Wuxi, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets metabolic diseases and oncology, with a specific emphasis on liver-related conditions such as nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Its lead programs include highly selective thyroid hormone receptor beta (THR-beta) agonists and FGFR4 inhibitors designed to address significant unmet medical needs. Wuxi Jialing Pharmaceutical leverages its internal R&D capabilities to advance a pipeline of candidates from early discovery through clinical proof-of-concept.